Mind the Gap is a new blog from Steve Wilkins gathering information and thoughts about communication between physicians and their patients… or lack thereof.

In his own words:

“Mind the Gap”  is a warning heard on subway systems around the world.  It is intended to alert individuals to avoid accidentally stepping in the “gap” that separates the train from the platform.

As used here, it is an expression that alludes to the communications gap that exists all too often today between patients and their physicians.   Like the subway, this blog is a kind of warning.  It is intended to making health care provider and organizations aware of the consequences of poor physician-patient communications…and how to avoid them.

Have a look at Mind the Gap. We’re sure there will be some nice informative gems in there that will trigger ideas on how big pharma or biotechs and their agencies can help HCPs better communicate with patients.

Description: People from different walks of life talk about cholesterol and how much they thought they knew about it and in reality they don’t. A spokesperson then comes in and talks about the risks associated with high cholesterol and its link with plaque buildup using animated visuals…

To see all of the ads from this campaign, click here

Brand name: Crestor
Generic name/category: Rosuvastatin, statins
Company: AstraZeneca
Country/Market: USA, North America
Indication(s)/use: high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia)
Target: Consumer (DTC)
Medium: TV commercial
Size/duration: 60 seconds
Publication: 2009

To see all Crestor ads, click here

From Wikipedia:
Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Shionogi developed the product and the pharmaceutical company AstraZeneca markets it as Crestor.

Rosuvastatin is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).

As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.

More on Wikipedia

Click here to see the details and full-size version of this ad on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click on image to view ad details and full-size version on AdPharm

To see all of this brand’s ads on AdPharm, click here

This GSK site in the UK is primarily an informal site on GSK drugs, what they do, and with quick access to the treatments’ patient information. There’s also a section to report adverse events.

Description of the site from GSK: This site is intended for the UK public only. It is designed to provide easy access to information about GSK UK products and their disease areas. The aim is to provide straightforward information on our products. Links are provided to the relevant support web sites to aid you in your search for information.

Public site
Entry page > Public home > Public sample drug information page > Public Adverse events reporting page

Healthcare professional site
Entry page > HCP home > HCP sample drug information page > HCP Adverse events reporting page

Click here to visit the site

To see all of the ads from this campaign, click here

Click on thumbnail to view the full-size ad on AdPharm

Acid reflux disease.
Burning. Bad taste in your throat. Belching.

Try AcipHex free for 2 weeks!
1-800-203-8672
TryAciphex.com/72

Brand name: AcipHex
Generic name/category: Rabeprazole, Prodrugs, Proton pump inhibitors, Benzimidazoles, Sulfoxides
Company: Eisai and PriCara
Country/Market: USA, North America
Indication(s)/use: Acid reflux disease
Target: Consumers (DTC) / Healthcare Professionals (HCP) / Trade
Tagline: Acid reflux disease. It’s got many faces.
Medium: Print ad
Size/duration: single-page
Publication/Aired: Ladies’ Home Journal – October 2009

To see all of this brand’s ads on AdPharm, click here

Living proof

ACS – PAD – Stroke – PAD – ACS
4 large trials involving more than 81,000 patients.

Plavix ??? the only prescription antiplatelet with proven efficacy and a well-established safety profile in a broad range of patients.

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix, by Sun Pharmaceuticals under the trade name Clopilet, by Ranbaxy Laboratories under the trade name Ceruvin. It works by irreversibly inhibiting a receptor called P2Y12. Adverse effects include hemorrhage.

More on Wikipedia

Brand name: Plavix
Generic name/category: Clopidogrel, Antiplatelet drugs, ADP receptor inhibitors, Thiophenes, Prodrugs
Company: Sanofi-Aventis and Bristol-Myers Squibb
Country/Market: USA, North America
Indication(s)/use: inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease
Target: Healthcare Professionals (HCP)
Tagline: Living Proof.
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: The Journal of Invasive Cardiology – September 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 11, 2009

Visit AdPharm.net for more pharmaceutical ads

Original Post: worldofdtcmarketing.com

Finally ! A pharma company gets it right ! Novartis has launched a website called CML Earth to connect CML patients worldwide to send support, hugs, or just to share stories. This is a great site and this what the Internet is all about..connecting people. I hope this site has a lot of success and that patients and caregivers find this valuable resource for people with CML. I thought the site was excellent and that it connects patients and caregivers worldwide to let them know they are not alone. Read the rest of this entry »